126 related articles for article (PubMed ID: 38195018)
1. Non-invasive decision support for clinical treatment of non-small cell lung cancer using a multiscale radiomics approach.
Zhang X; Zhang G; Qiu X; Yin J; Tan W; Yin X; Yang H; Wang H; Zhang Y
Radiother Oncol; 2024 Feb; 191():110082. PubMed ID: 38195018
[TBL] [Abstract][Full Text] [Related]
2. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
3. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
[TBL] [Abstract][Full Text] [Related]
4. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
6. Exploring non-invasive precision treatment in non-small cell lung cancer patients through deep learning radiomics across imaging features and molecular phenotypes.
Zhang X; Zhang G; Qiu X; Yin J; Tan W; Yin X; Yang H; Wang H; Zhang Y
Biomark Res; 2024 Jan; 12(1):12. PubMed ID: 38273398
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
8. Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer.
Le NQK; Kha QH; Nguyen VH; Chen YC; Cheng SJ; Chen CY
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502160
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
[TBL] [Abstract][Full Text] [Related]
10. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
11. Impact of feature harmonization on radiogenomics analysis: Prediction of EGFR and KRAS mutations from non-small cell lung cancer PET/CT images.
Shiri I; Amini M; Nazari M; Hajianfar G; Haddadi Avval A; Abdollahi H; Oveisi M; Arabi H; Rahmim A; Zaidi H
Comput Biol Med; 2022 Mar; 142():105230. PubMed ID: 35051856
[TBL] [Abstract][Full Text] [Related]
12. Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.
Yip SS; Kim J; Coroller TP; Parmar C; Velazquez ER; Huynh E; Mak RH; Aerts HJ
J Nucl Med; 2017 Apr; 58(4):569-576. PubMed ID: 27688480
[TBL] [Abstract][Full Text] [Related]
13. Hybrid deep multi-task learning radiomics approach for predicting EGFR mutation status of non-small cell lung cancer in CT images.
Gong J; Fu F; Ma X; Wang T; Ma X; You C; Zhang Y; Peng W; Chen H; Gu Y
Phys Med Biol; 2023 Dec; 68(24):. PubMed ID: 37972417
[No Abstract] [Full Text] [Related]
14. A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study.
Tong H; Sun J; Fang J; Zhang M; Liu H; Xia R; Zhou W; Liu K; Chen X
Front Immunol; 2022; 13():859323. PubMed ID: 35572597
[TBL] [Abstract][Full Text] [Related]
15. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
16. CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer.
Wang J; Wang J; Huang X; Zhou Y; Qi J; Sun X; Nie J; Hu Z; Wang S; Hong B; Wang H
BMC Med Imaging; 2024 Feb; 24(1):45. PubMed ID: 38360550
[TBL] [Abstract][Full Text] [Related]
17. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
20. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT
Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]